Zydus Cadila has received the final approval from the U.S. drug regulator to market an antibiotic used for treating bacterial infections.
The company’s Doxycycline Hyclate capsules USP got the approval from the U.S. Food and Drug Administration, according a stock exchange filing by Cadila Healthcare. It is a tetracycline antibiotic which is used for the treatment of a wide variety of bacterial infections, including those that cause acne.
"This medication is also used for prophylaxis of malaria," the filing said. The capsules will be manufactured at the group's manufacturing facility at the special economic zone in Ahmedabad, Gujarat.
The group has now more than 195 approvals so far.